These findings collectively indicate that Oxalis phytochemicals exhibit promising MAO-B inhibitory potential, with beta-sitosterol, rhoifolin, and swertisin being possibly the strong drug candidates for the therapeutic applications in age related neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Here, MAOB is linked to Parkinsonism.